PCRX earnings date and last-quarter result: last quarter miss, P/E 209.58. Updated 2026-07-23.
Pacira BioSciences (PCRX) Research Hub
Pacira BioSciences (PCRX) trades on NASDAQ, US in the Healthcare (Drug Manufacturers - Specialty & Generic) sector. As of 2026-10-26, shares last closed at 36.38 USD (-0.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 209.58, market cap 1.00B. This hub links to the full technical, earnings and options research available for PCRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - Specialty & Generic) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 36.38 USD (-0.11%) |
| 52-week range | 22 USD – 36.665 USD |
| Trend regime | Range |
| 14-day RSI | 97.7 (Overbought) |
| Trailing P/E | 209.58 |
| Market cap | 1.00B |
| Dividend yield | 0.00% |
Available research for PCRX
Covered Call on PCRX: how it works, illustrative setup around the real 36.38 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PCRX: how it works, illustrative setup around the real 36.38 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PCRX: how it works, illustrative setup around the real 36.38 USD price, max profit/loss, breakeven and when to use it. Educational.
PCRX technical analysis: range, last 36.38 USD, RSI 97.7, 52w range 22 USD–36.665 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PCRX in?
Pacira BioSciences (PCRX) is classified under Healthcare (Drug Manufacturers - Specialty & Generic), listed on NASDAQ, US.
Is PCRX in an uptrend or downtrend?
As of 2026-10-26, PCRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PCRX's trailing P/E ratio?
PCRX's trailing P/E is 209.58, with a market cap of 1.00B. See the earnings research page for full valuation detail.